Solid Biosciences Inc. (SLDB)
NASDAQ: SLDB · Real-Time Price · USD
7.45
-0.05 (-0.67%)
At close: Apr 28, 2026, 4:00 PM EDT
7.38
-0.07 (-0.94%)
After-hours: Apr 28, 2026, 7:49 PM EDT
Solid Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
121
Market Cap
733.04M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 8.09M | -5.53M | -40.57% |
| Dec 31, 2021 | 13.62M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Gyre Therapeutics | 116.59M |
| ARS Pharmaceuticals | 84.28M |
| Lexicon Pharmaceuticals | 49.80M |
| Absci | 2.80M |
| Allogene Therapeutics | 22.00K |
SLDB News
- 13 hours ago - Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy - GlobeNewsWire
- 14 days ago - Solid Biosciences Transcript: 25th Annual Needham Virtual Healthcare Conference - Transcripts
- 21 days ago - Solid Biosciences to Participate at Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 6 weeks ago - Solid Biosciences Transcript: Barclays 28th Annual Global Healthcare Conference - Transcripts
- 6 weeks ago - Solid Biosciences Touts Encouraging Results For Duchenne Gene Therapy, FDA Talks Planned - Benzinga
- 6 weeks ago - Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial - GlobeNewsWire
- 7 weeks ago - Solid Biosciences Announces Oversubscribed $240 Million Private Placement - GlobeNewsWire